BioCentury
ARTICLE | Clinical News

Bavarian Nordic reports Phase II data for MVA-BN RSV for respiratory syncytial virus

November 30, 2017 11:44 PM UTC

In September, Bavarian Nordic A/S (CSE:BAVA) reported data from a Phase II trial in 421 healthy volunteers aged ≥55 showing that MVA-BN RSV led to a persistent antibody response against undisclosed RSV targets at 6 months post-vaccination. The single-blind, placebo-controlled U.S. trial is evaluating 2 dose levels of MVA-BN RSV given once or twice 4 weeks apart to vaccinate against respiratory syncytial virus (RSV). The primary endpoint is plaque reduction neutralization, tested at 2 weeks after the last vaccination. The secondary endpoint is safety...

BCIQ Company Profiles

Bavarian Nordic A/S

BCIQ Target Profiles

RSV F protein

RSV G protein